MN2 Stock Chart & Stats
€1.20
€0.00(0.00%)
At close: 4:00 PM EST
€1.20
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.80 - €1.42
Previous CloseN/A
Volume0.00
Average Volume (3M)106.00
Market Cap
€37.87M
Enterprise Value€325.16
Total Cash (Recent Filing)€61.07M
Total Debt (Recent Filing)€13.56M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Nov 10, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding28,125,734
10 Day Avg. Volume0
30 Day Avg. Volume106
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)2.71
Price to Sales (P/S)1.34
P/FCF Ratio-14.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)€28.15M
Bulls Say, Bears Say
Bulls Say
Niche Simulation Product OfferingMentice’s specialized VR/haptics simulation platform and procedure content target a high-value niche: image-guided endovascular training. This specialization creates durable product differentiation, strong B2B relationships with hospitals and device makers, and recurring content/license demand.
Improving Revenue TrendConsistent TTM revenue growth and improved profitability versus the prior year indicate rising adoption of Mentice’s offerings. Sustained top-line expansion supports scale benefits in content creation and recurring-license economics, enabling continued margin recovery and reinvestment in product development.
Conservative LeverageVery low debt-to-equity gives Mentice durable financial flexibility to fund R&D and commercial expansion without heavy interest burden. Conservative leverage reduces refinancing risk, supports multi-year investment cycles typical in medical training tech, and strengthens resilience during revenue variability.
Bears Say
Ongoing Losses / Negative ROEDespite improvements, persistent negative EBIT/net income and below-zero ROE limit internal capital generation and the company’s ability to self-fund growth. Continued losses constrain strategic optionality, slow return on invested capital, and require either sustained margin improvement or external financing to reach durable profitability.
Volatile Cash GenerationOperating and free cash flow swung materially across recent years, reflecting execution and working-capital variability. This unpredictability complicates multi-quarter planning for product rollouts and content investment and raises the likelihood of intermittent financing needs during weaker cash periods.
Limited Scale / Concentration RiskA small headcount and a focused customer base suggest constrained internal capacity and potential customer concentration. That limits ability to rapidly scale multi-site deployments, raises per-deal resource intensity, and makes revenue more sensitive to a handful of large B2B contracts over time.
Mentice AB News
MN2 FAQ
What was Mentice AB’s price range in the past 12 months?
Mentice AB lowest stock price was €0.80 and its highest was €1.42 in the past 12 months.
What is Mentice AB’s market cap?
Mentice AB’s market cap is €37.87M.
When is Mentice AB’s upcoming earnings report date?
Mentice AB’s upcoming earnings report date is Nov 10, 2026 which is in 102 days.
How were Mentice AB’s earnings last quarter?
Mentice AB released its earnings results on Jul 23, 2026. The company reported -€0.001 earnings per share for the quarter, beating the consensus estimate of -€0.009 by €0.008.
Is Mentice AB overvalued?
According to Wall Street analysts Mentice AB’s price is currently Overvalued.
Does Mentice AB pay dividends?
Mentice AB does not currently pay dividends.
What is Mentice AB’s EPS estimate?
Mentice AB’s EPS estimate is >-0.01.
How many shares outstanding does Mentice AB have?
Mentice AB has 28,125,734 shares outstanding.
What happened to Mentice AB’s price movement after its last earnings report?
Mentice AB reported an EPS of -€0.001 in its last earnings report, beating expectations of -€0.009. Following the earnings report the stock price went up 4.367%.
Which hedge fund is a major shareholder of Mentice AB?
Currently, no hedge funds are holding shares in DE:MN2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mentice AB
Mentice AB (publ), founded in 1998 and headquartered in Gothenburg, Sweden, specializes in delivering advanced endovascular simulation solutions. These are utilized by educational institutions, healthcare systems, and medical device manufacturers globally, with the company's operations spanning across Europe, the Middle East, Africa, the Asia Pacific region, and the Americas. Its business is structured across distinct segments focusing on the Medical Device Industry, Healthcare Systems, and Strategic Alliances. The company offers a comprehensive suite of software modules designed for training in a wide array of interventional procedures. These include acute ischemic stroke, atrial septal defect/patent foramen ovale occlusion, aortic valve implantation, endovascular aortic repair, below-the-knee, carotid, and renal interventions, along with patient-specific simulations. The portfolio further encompasses advanced and essential coronary procedures, intermediate coronary, left atrial appendage occlusion, neurovascular coiling and thrombectomy, peripheral angiography, prostatic and uterine artery embolization, radiation safety, transarterial chemoembolization, transseptal puncture, vascular trauma, and cardiac rhythm management. Additionally, Mentice provides crucial support for interventionalists transitioning from transfemoral to transradial access techniques. Beyond software, Mentice's product line features sophisticated medical simulators for endovascular therapies, accompanied by compatible accessories and extensions. They also supply specialized silicone vasculature, as well as cardiac, vascular, and neurovascular flow systems. Innovative digital offerings include the Mentice Right Heart Cath App, a mobile tool for interactive exploration of right heart catheterization procedures, and the Mentice Live Learning Center, which facilitates remote learning through its VIST G endovascular simulation platform. All these comprehensive solutions are engineered to educate, train, and significantly enhance the skills of medical professionals.
Technical Analysis
Clinical Laserthermia Systems AB Class B
―
Bactiguard Holding AB
―
C-Rad AB Class B
―
Acarix AB
―
BrainCool AB
―